Needham & Company LLC Lowers LivaNova (NASDAQ:LIVN) Price Target to $64.00

LivaNova (NASDAQ:LIVN) had its target price decreased by Needham & Company LLC from $75.00 to $64.00 in a research note issued to investors on Wednesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Mizuho reduced their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $64.20.

LivaNova Stock Up 1.7 %

LivaNova stock opened at $41.63 on Wednesday. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 99.12 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company’s 50-day moving average price is $47.40 and its two-hundred day moving average price is $49.49. LivaNova has a 52 week low of $40.37 and a 52 week high of $64.47.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after buying an additional 289 shares during the period. Atria Investments Inc boosted its holdings in shares of LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares during the period. Finally, Xponance Inc. boosted its holdings in shares of LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after buying an additional 445 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.